Showing 15 posts of 258 posts found.

Bayer’s cardiovascular drug shows impressive Phase III results

May 11, 2021
Manufacturing and Production Bayer, chronic kidney disease, pharma, pharma news, type 2 diabetes

Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events in patients with chronic kidney …


Bayer’s venous thromboembolism drug Xarelto gets UK approval for children

February 1, 2021
Sales and Marketing Bayer

Bayer has received UK approval for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism …

Bayer and CureVac to collaborate on COVID-19 vaccine candidate

January 8, 2021
Medical Communications Bayer, COVID-19, Vaccine

Bayer is joining forces with CureVac, a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA), on its COVID-19 …

Bayer buys out US-based Asklepios BioPharmaceutical in potential $4bn deal

October 26, 2020
Sales and Marketing Asklepios, Bayer, acquisition, pharma

Bayer has moved to bolster its cell and gene therapy (CGT) business through the acquisition of US biotech Asklepios BioPharmaceutical …


Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis

October 23, 2020
Medical Communications, Sales and Marketing Bayer, NCIE, Nubeqa, pharma

NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for …


Bayer scoops up women’s healthcare biotech KaNDy Therapeutics in potential $1bn+ deal

August 11, 2020
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, KaNDy Therapeutics, menopause, pharma

Bayer is set to acquire UK-based biotech KaNDy Therapeutics, assimilating the firm’s women’s healthcare development portfolio in a newly announced …


FDA grants fast review for Bayer and MSD’s heart failure drug vericiguat

July 17, 2020
Medical Communications Bayer, FDA, MSD

The FDA has granted a fast Priority Review for Bayer and MSD’s heart failure drug vericiguat. This was based on …

Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer

April 21, 2020
Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …

Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer

March 31, 2020
Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer

The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …


GW Pharma takes back control of UK Sativex sales from Bayer

March 2, 2020
Sales and Marketing Bayer, GW Pharma, Sativex, UK

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …

Bayer’s Eylea shows strong vision benefits across two regimens in post-marketing study

February 5, 2020
Research and Development Bayer, Eylea, pharma

Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment …


Bayer and Orion’s Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer

January 31, 2020
Medical Communications, Research and Development Bayer, orion, pharma

Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen …

NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns

January 20, 2020
Sales and Marketing Bayer, Cancer, NICE, Vitravki

UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …


Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery

January 10, 2020
Medical Communications Bayer, Exscientia, oncology

Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. …


Bayer and MSD’s chronic heart failure drug meets main goal at Phase 3

November 19, 2019
Manufacturing and Production, Research and Development Bayer, MSD, pharma, vericiguat

MSD and Bayer have made it known that their jointly-developed soluble guanylate cyclase (sGC) stimulator vericiguat met its primary endpoint …

Latest content